Čájehuvvojit 1 - 2 oktiibuot 2 bohtosis ohcui Muhammad Javad Muhammadi', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial

    Study rationale and design of a study of EMPAgliflozin’s effects in patients with type 2 diabetes mellitus and Coronary ARtery disease: the EMPA-CARD randomized controlled trial Dahkki Sepehr Gohari, Tara Reshadmanesh, Hadi Khodabandehloo, Mojtaba Fathi, Hassan Ahangar, Shahram Arsang-Jang, Faramarz Ismail-Beigi, Samin Ghanbari, Mohsen Dadashi, Muhammad Javad Muhammadi, Sheida Gohari, Saeid Ghaffari

    Almmustuhtton 2021-06-01
    Viečča ollesdeavstta
    Artihkal
  2. 2
    The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial

    The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial Dahkki Sepehr Gohari, Tara Reshadmanesh, Hadi Khodabandehloo, Amir Karbalaee-Hasani, Hassan Ahangar, Shahram Arsang-Jang, Faramarz Ismail-Beigi, Mohsen Dadashi, Samin Ghanbari, Homa Taheri, Mojtaba Fathi, Muhammad Javad Muhammadi, Reyhaneh Mahmoodian, Atieh Asgari, Mohammadreza Tayaranian, Mehdi Moharrami, Mahsa Mahjani, Bijan Ghobadian, Hossein Chiti, Sheida Gohari

    Almmustuhtton 2022-11-01
    Viečča ollesdeavstta
    Artihkal

Ohcanreaiddut: